Evidence map›Paper›PMID 33913081›Full record

ArticleClinical drug investigation2021

Comparison of Pharmacokinetic Profiles of Beraprost Sustained Release in Japanese, Chinese, and Korean Healthy Adult Males.

Ikumi Nakajo, Hiroshi Inoue, Masaki Inaba, Keishi Oikawa, Masataka Katashima, Taiji Sawamoto, Hajimu Kurumatani, Masanari Shiramoto

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical drug investigation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 91% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Ikumi NakajoAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan. ikumi.nakajo@astellas.com.
Hiroshi InoueAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
Masaki InabaAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
Keishi OikawaAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
Masataka KatashimaAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
Taiji SawamotoAstellas Pharma Inc., 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, 103-8411, Japan.
Hajimu KurumataniToray Industries, Inc., Tokyo, Japan.
Masanari ShiramotoSOUSEIKAI Hakata Clinic, Fukuoka, Japan.
Astellas Pharma (Japan) · JPSOUSEIKAI Global Clinical Research Center · JPToray Industries, Inc. (Japan) · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND AND

objectivesBeraprost sodium (BPS), an orally administrable prostaglandin I

methodsTwelve healthy subjects in each ethnic group were enrolled. Subjects received a single oral dose of 120 μg beraprost SR under fasting conditions.

resultsThe geometric mean ratio (90% confidence interval) of the maximum plasma concentration (C

conclusionsThere were no clinically meaningful ethnic differences in the pharmacokinetics of BPS and BPS-314d following beraprost SR administration among Japanese, Chinese and Korean populations.

Indexed as

Administration, OralAdultAsian PeopleChinaDelayed-Action PreparationsEpoprostenolFastingHumansJapanMaleRepublic of KoreaYoung AdultberaprostDelayed-Action PreparationsEpoprostenol

Identifiers

PMID33913081
OpenAlexW3159825781

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.